TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary: The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.


Options:
A: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D
B: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
D: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary: The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.


Options:
A: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D
B: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
C: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
D: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary: The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.


Options:
A: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary: The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D
C: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2A, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE PILOT EFFICACY, SAFETY, AND PHARMACOKINETICS OF 2 OINTMENT FORMULATIONS OF CP-690,550 IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
Brief Summary: The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.


Options:
A: Arm Label: CP 690,550 5 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 5 mg | Arm Label: CP 690,550 10 mg BID+Placebo BIW; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 10 mg | Arm Label: Placebo BID+Etanercept 50 mg BIW; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept 50 mg | Arm Label: Placebo BID+Placebo BIW; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP 690,550 5 mg; Assigned to Arm(s): CP 690,550 5 mg BID+Placebo BIW | Intervention Type: DRUG; Name: CP 690,550 10 mg; Assigned to Arm(s): CP 690,550 10 mg BID+Placebo BIW | Intervention Type: BIOLOGICAL; Name: Etanercept 50 mg; Assigned to Arm(s): Placebo BID+Etanercept 50 mg BIW | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo BID+Placebo BIW
B: Arm Label: Risankizumab; Type: EXPERIMENTAL; Interventions: Drug: Risankizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Risankizumab; Assigned to Arm(s): Risankizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
D: Arm Label: Treatment Group A; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 1 | Arm Label: Treatment Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 1 | Arm Label: Treatment Group C; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 Ointment 2 | Arm Label: Treatment Group D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle 2 | Intervention Type: DRUG; Name: CP-690,550 Ointment 1; Assigned to Arm(s): Treatment Group A | Intervention Type: DRUG; Name: Vehicle 1; Assigned to Arm(s): Treatment Group B | Intervention Type: DRUG; Name: CP-690,550 Ointment 2; Assigned to Arm(s): Treatment Group C | Intervention Type: DRUG; Name: Vehicle 2; Assigned to Arm(s): Treatment Group D

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department
Brief Summary: The purpose of this study is to determine whether nebulized 3% hypertonic saline (HS) improves respiratory distress in children 2-23 months presenting to the emergency department (ED) with acute bronchiolitis with persistent respiratory distress after initial therapy with a trial of nebulized albuterol.


Options:
A: Arm Label: NaCl 3% inhalations + standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: NaCl 3%, Other: Standard therapy | Arm Label: Standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard therapy | Intervention Type: DRUG; Name: NaCl 3%; Assigned to Arm(s): NaCl 3% inhalations + standard therapy | Intervention Type: OTHER; Name: Standard therapy; Assigned to Arm(s): NaCl 3% inhalations + standard therapy, Standard therapy
B: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
C: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% saline; Assigned to Arm(s): Nebulized 0.9% Saline
D: Arm Label: Nebulized Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% sodium chloride | Arm Label: Nebulized Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% sodium chloride | Intervention Type: DRUG; Name: 3% sodium chloride; Assigned to Arm(s): Nebulized Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% sodium chloride; Assigned to Arm(s): Nebulized Normal Saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department
Brief Summary: The purpose of this study is to determine whether nebulized 3% hypertonic saline (HS) improves respiratory distress in children 2-23 months presenting to the emergency department (ED) with acute bronchiolitis with persistent respiratory distress after initial therapy with a trial of nebulized albuterol.


Options:
A: Arm Label: heliox; Type: OTHER; Interventions: Drug: heliox | Arm Label: oxygen; Type: OTHER; Interventions: Drug: oxygen | Intervention Type: DRUG; Name: heliox; Assigned to Arm(s): heliox | Intervention Type: DRUG; Name: oxygen; Assigned to Arm(s): oxygen
B: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
C: Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albuterol (salbutamol); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: nebulized epinephrine and nebulized albuterol; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department
Brief Summary: The purpose of this study is to determine whether nebulized 3% hypertonic saline (HS) improves respiratory distress in children 2-23 months presenting to the emergency department (ED) with acute bronchiolitis with persistent respiratory distress after initial therapy with a trial of nebulized albuterol.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 0.9% saline | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 3% hypertonic saline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 0.9% saline; Assigned to Arm(s): 2
B: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
C: Arm Label: HSS (3%) + epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epinephrine 1/1000, Drug: HSS 3% | Arm Label: HHHFNC+epinephrine+Normal Saline(0.9%); Type: EXPERIMENTAL; Interventions: Drug: Epinephrine 1/1000, Device: HHHFNC, Drug: NS (0.9%) | Intervention Type: DRUG; Name: Epinephrine 1/1000; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%), HSS (3%) + epinephrine | Intervention Type: DRUG; Name: HSS 3%; Assigned to Arm(s): HSS (3%) + epinephrine | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%) | Intervention Type: DRUG; Name: NS (0.9%); Assigned to Arm(s): HHHFNC+epinephrine+Normal Saline(0.9%)
D: Arm Label: 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: 3% Saline | Arm Label: 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Normal Saline | Intervention Type: DRUG; Name: 3% Saline; Assigned to Arm(s): 3% Saline | Intervention Type: DRUG; Name: 0.9% Normal Saline; Assigned to Arm(s): 0.9% Normal Saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Adherence to HAART Using Mobile Phone Text Messages
Brief Summary: The investigators hypothesize that sending weekly motivational text messages to people infected with HIV will encourage them to take their medication, compared to usual care.


Options:
A: Arm Label: Mobile phone text message; Type: EXPERIMENTAL; Interventions: Other: Mobile phone text message | Arm Label: No Mobile phone text message; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Mobile phone text message; Assigned to Arm(s): Mobile phone text message | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): No Mobile phone text message
B: Arm Label: Individualized, interactive SMS; Type: EXPERIMENTAL; Interventions: Behavioral: Individualized, interactive short messaging intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Individualized, interactive short messaging intervention; Assigned to Arm(s): Individualized, interactive SMS
C: Arm Label: ARM 1 = TEXT MESSAGING SUPPORT; Type: EXPERIMENTAL; Interventions: Drug: nPEP, Behavioral: Text Messaging Support | Arm Label: ARM 2 = NO TEXT MESSAGING SUPPORT; Type: EXPERIMENTAL; Interventions: Drug: nPEP | Arm Label: ARM 3 = NURSE-LED nPEP; Type: EXPERIMENTAL; Interventions: Drug: nPEP, Other: Nurse-Led nPEP | Arm Label: ARM 4 = ID PHYSICIAN-LED nPEP,; Type: ACTIVE_COMPARATOR; Interventions: Drug: nPEP | Intervention Type: DRUG; Name: nPEP; Assigned to Arm(s): ARM 1 = TEXT MESSAGING SUPPORT, ARM 2 = NO TEXT MESSAGING SUPPORT, ARM 3 = NURSE-LED nPEP, ARM 4 = ID PHYSICIAN-LED nPEP, | Intervention Type: BEHAVIORAL; Name: Text Messaging Support; Assigned to Arm(s): ARM 1 = TEXT MESSAGING SUPPORT | Intervention Type: OTHER; Name: Nurse-Led nPEP; Assigned to Arm(s): ARM 3 = NURSE-LED nPEP
D: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Adherence to HAART Using Mobile Phone Text Messages
Brief Summary: The investigators hypothesize that sending weekly motivational text messages to people infected with HIV will encourage them to take their medication, compared to usual care.


Options:
A: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS text message; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message | Arm Label: SMS text message + Peer Navigation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message + Peer Navigation | Intervention Type: BEHAVIORAL; Name: SMS text message; Assigned to Arm(s): SMS text message | Intervention Type: BEHAVIORAL; Name: SMS text message + Peer Navigation; Assigned to Arm(s): SMS text message + Peer Navigation
B: Arm Label: Standard + Pamphlet; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pamphlet | Arm Label: Group 2: standard + facebook; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facebook | Intervention Type: BEHAVIORAL; Name: Facebook; Assigned to Arm(s): Group 2: standard + facebook | Intervention Type: BEHAVIORAL; Name: Pamphlet; Assigned to Arm(s): Standard + Pamphlet
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Quit4Baby, Behavioral: Text4Baby | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Text4Baby | Intervention Type: BEHAVIORAL; Name: Quit4Baby; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Text4Baby; Assigned to Arm(s): Control, Intervention
D: Arm Label: Mobile phone text message; Type: EXPERIMENTAL; Interventions: Other: Mobile phone text message | Arm Label: No Mobile phone text message; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Mobile phone text message; Assigned to Arm(s): Mobile phone text message | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): No Mobile phone text message

Answer: D